It's Time For a Quick Look at ICON's Fundamentals.

By Blake Campbell • Wednesday, January 10 15:11 • Permanent Link

One of the losers of today's trading session was ICON. Shares of the Biotechnology company plunged -4.5%, and some investors may be wondering if its price of $259.04 would make a good entry point. Here's what you should know if you are considering this investment:

ICON has moved 21.7% over the last year, and the S&P 500 logged a change of 20.0%
ICLR has an average analyst rating of buy and is -15.58% away from its mean target price of $306.86 per share
Its trailing earnings per share (EPS) is $6.21
ICON has a trailing 12 month Price to Earnings (P/E) ratio of 41.7 while the S&P 500 average is 15.97
Its forward earnings per share (EPS) is $14.87 and its forward P/E ratio is 17.4
The company has a Price to Book (P/B) ratio of 2.38 in contrast to the S&P 500's average ratio of 2.95
ICON is part of the Health Care sector, which has an average P/E ratio of 30.21 and an average P/B of 4.08
ICLR has reported YOY quarterly earnings growth of 1.5% and gross profit margins of 0.3%
The company has a free cash flow of $444.39 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It offers clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; and clinical research services, including biostatistics, clinical operations, clinical supplies management, covid-19, data management, decentralized & hybrid clinical solutions, endpoint adjudication services, interactive response technologies, investigator payments, medical affairs, medical writing and publishing, pharmacovigilance, and site and patient solutions. The company also provides laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. In addition, it offers commercial positioning, early phase, language, medical imaging, and strategic solutions, as well as clinical trial management, consulting, and contract staffing services. The company serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1990 and is headquartered in Dublin, Ireland.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.